Novavax is trading at $11.54, down -10.02%, as investors reassess enthusiasm around the Russian plague scare after the WHO said the risk to the general population appeared low.

  • On October 16, 2026, recent coverage linked Novavax and other vaccine-stock declines to that reassessment, not to a new company announcement.
  • Biotech was down 2.06%, adding industry pressure; no clear company-specific catalyst was identified.